Express Mail: EV 630723202 US

Preliminary Amendment A

Appl. No. TBA April 26, 2006

Amendments to the Specification

Please insert the following headings at line 2 on page 1:

PRIORITY CLAIM TO RELATED PATENT APPLICATIONS

This patent claims priority under 35 U.S.C. §371 as a national phase of International Patent Application No. PCT/EP2004/052763 (filed November 3, 2004; and published on May 26, 2005 as International Publication No. WO 2005/046656), which, in turn, claims priority to European Patent Application No. 03078484.7 (filed November 4, 2003). The entire text of each of the above-referenced patent applications is hereby incorporated by referenced into this patent.

FIELD OF THE INVENTION

Please <u>amend</u> the paragraph bridging lines 3-5 on page 1 in the following manner:

The invention is related to the use of haloarylpyrazole compounds for deterring ticks, and to an administration regimen of specific haloarylpyrazole compounds for the control of ticks on animals, and the use of haloarylpyrazole compounds to prepare medicaments for deterring ticks.

Please <u>insert</u> the following heading at line 6 on page 1:

BACKGROUND OF THE INVENTION

Please <u>insert</u> the following heading before line 22 on page 2:

BRIEF SUMMARY OF THE INVENTION

Please insert the following paragraphs and headings at line 25 on page 2:

This invention is directed, in part, to a method for deterring ticks from infesting an animal.

Express Mail: EV 630723202 US Preliminary Amendment A Appl. No. TBA April 26, 2006

In one embodiment, the method comprises administering a haloarylpyrazole to the animal. The haloarylpyrazole corresponds in structure to formula (I):

$$\begin{array}{c|c}
W & CH_2)_n(A)_p & R_2 \\
N & R_3 \\
R_4 & R_3
\end{array}$$
(I).

Here:

Ar is 2,6-dichloro-4-trifluoromethylphenyl or 2-nitro-4-trifluoromethylphenyl.

A is $S(O)_m$, CH=CH, O, or NH.

As to W and Z, W is N, and Z is CR⁵. Alternatively, W is CR¹, and Z is N or CR⁵.

R¹ is hydrogen, optionally substituted alkyl, halogen, or R²⁰S(O)_q.

 R^2 and R^3 are hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, aryl, cyano, halogen, nitro, YR^{20} , $S(O)_2NR^8R^9$, CHO, NR^8R^9 , or $CYNR^8R^9$.

R⁴ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, acyl, or optionally substituted alkoxycarbonyl.

R⁵ is hydrogen, alkyl, optionally substituted amino, or halogen.

R⁸ and R⁹ are independently hydrogen, optionally substituted alkyl, acyl, or aryl.

R²⁰ is optionally substituted alkyl.

Y is O or S.

m, n, and q are independently zero, 1, or 2.

p is zero or 1.

Any alkyl, alkoxy, or alkylthio comprises 1 to 4 carbon atoms.

Any alkenyl or alkynyl comprises 2 to 5 carbon atoms.

Any alkyl, alkoxy, alkylthio, alkenyl, or alkynyl portion of a substituted alkyl, alkoxy, alkylthio, alkenyl, or alkynyl is substituted by one or more substituents independently selected

Express Mail: EV 630723202 US Preliminary Amendment A Appl. No. TBA April 26, 2006

from the group consisting of halogen, YR²⁰, dihalocyclopropyl, cyano, nitro, optionally substituted amino, acyloxy, and aryl.

Any aryl is phenyl optionally substituted by halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, haloalkylsulphonyl, cyano, or nitro.

Any acyl is alkanoyl comprising 1 to 4 carbon atoms, alkylsulphonyl, or haloalkylsulphonyl.

Any optionally substituted amino is NR⁸R⁹.

R⁴ is not alkyl when (1) W is CR¹, (2) Z is CR⁵, and (3) n and p are both zero.

In another embodiment, the method comprises orally administering an initial dose of 4 mg of 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole per kg bodyweight of the animal. Following the initial dose, weekly oral doses of 2 mg 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole per kg bodyweight of the animal are administered.

This invention also is directed, in part, to a use of a haloarylpyrazole of formula (I) for making a medicament to deter ticks from an animal.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the overall efficacy against ticks (Rhipicephalus sanguineus) observed using 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl)-3-isopropyl-1H-pyrazole with dogs.

Figure 2 shows the repellence effect against ticks (Rhipicephalus sanguineus) observed using 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl)-3-isopropyl-1H-pyrazole with dogs.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Please insert the following abstract at the end of the specification (a copy of the abstract on a clean page has been enclosed with this amendment):

ABSTRACT

Express Mail: EV 630723202 US Preliminary Amendment A Appl. No. TBA April 26, 2006

The present invention relates to the use of haloarylpyrazoles as tick-repellent compositions, and to an administration regimen of specific haloarylpyrazoles for controlling ticks on animals.